Genetic test to find minimal residual myeloma in remission
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a genetic technology (ClonoSeq-based) to detect very small amounts of multiple myeloma that may remain after treatment. It may help doctors better track how well treatment is working and predict how the disease responds over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of multiple myeloma (MM).
- You are a transplant-eligible person who is in your first remission (the disease is controlled after initial treatment).
- You already have an MRD result available from ClonoSeq (a genetic test that looks for tiny remaining cancer).
- You must be able to share basic, de-identified information about you and follow-up outcomes for the study.
- You are receiving standard (usual) treatment for multiple myeloma.
- You can provide informed consent (or consent is obtained through the study process).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for multiple myeloma patients who have achieved a stringent complete remission (sCR) for at least six months. It uses a blood test to look for very small traces of myeloma cells, which may help monitor treatment success.
This study is for people with newly diagnosed multiple myeloma whose cancer responded to initial treatment but still has tiny traces (minimal residual disease, or MRD). The trial will test if adjusting the next phase of therapy based on MRD levels can improve long-term outcomes.
This study looks at whether small leftover signs of multiple myeloma in blood or bone marrow (called measurable residual disease, or MRD) can predict how well treatment works. It involves people already taking study treatment in a larger trial and checks results about two years later to see who benefits most.
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
This study looks at whether people with newly diagnosed multiple myeloma can safely continue or adjust treatment after they reach “MRD-negative,” meaning very low signs of disease in the bone marrow. It may help reduce the chance of relapse while avoiding unnecessary treatment for some patients.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.